Imara Inc. (Nasdaq: IMRA), today announced the presentation of data from its nuclear factor erythroid 2-related factor 2 (Nrf2) activator program, IMR-261, at the American Society of Hematology (ASH) ...
Six months of treatment with oral IMR-687 safely and effectively reduced the number of vaso-occlusive crises (VOCs) and other disease-associated pain crises in adults with sickle cell disease (SCD), ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback